Menlo Park, CA (PRWEB) June 16, 2014
Life Science Strategy Group (LSSG), a leading strategic consulting firm to the CRO industry, is pleased to announce the availability of its 2014 syndicated report, “The Future of Pharma Outsourcing”. This new benchmark study with over 100 OutsourcePharma Advisory Board members (http://www.outsourcepharma.com), focuses on future use of outsourced development services providers including sponsor utilization of, satisfaction with, and rationale for use of strategic partnerships, preferred partners, and functional outsourcing. The report also explores service bundling trends, evolving sponsor-CRO relationship models, offshoring and utilization of niche providers, including contract negotiation and management.
“This report presents novel, proprietary data collected from a quantitative global sample of outsourcing professionals at biopharmaceutical companies and explores how various outsourcing methods are expected to evolve over the next five years. The data clearly show that large biopharmaceutical companies will increasingly rely upon large CROs, like Covance, Quintiles, PPD and Parexel among others, in the future,” said Jon Meyer, Co-founder and CRO Practice Leader of Life Science Strategy Group, LLC.
To learn more about this new syndicated report or to download sample pages, visit http://www.lifesciencestrategy.com/publications/cro-industry/pubs-cro-future-of-pharma-june-2014/.
About Life Science Strategy Group, LLC
Life Science Strategy Group, LLC specializes in strategic consulting, market research engagements and syndicated publications across a variety of therapeutic, technology and service industries including contract research services, pharmaceutical, biotechnology, medical devices, diagnostics and drug discovery.